Tweets
Among 784,091 pts in a UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities https://t.co/78oHVWTdTJ
Dr. John Cush @RheumNow ( View Tweet )
14 minutes 39 seconds ago
Nerandomilast (Jascayd) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug was approved for IPF & PPF by the FDA for US use in late 2025 https://t.co/scOuVb3aYy https://t.co/EcmpRhyWgu
Dr. John Cush @RheumNow ( View Tweet )
2 hours 14 minutes ago
Coding: ICD-10 Code M45.7 describes ankylosing spondylitis of the lumbosacral region, a billable ICD-10-CM diagnosis code valid for FY2026. M45.7 became effective October 1, 2025 and belongs to the M45 parent category covering ankylosing spondylitis by anatomical site. https://t.co/jBmoD0CVps
Dr. John Cush @RheumNow ( View Tweet )
3 hours 45 minutes ago
Chinese cohort of 209 AOSD pts identifed 49 (23%) w/ lung dz (by CXR), yet 69% were asymptomatic. Significcant risk factors for AOSD-LD were pleuritis, MAS (HR 2.62), & Dz relapse (HR 2.6). Imaging patterns: acute exudative pattern most prevalent, followed by interstitial and https://t.co/2IPJWRJicP
Dr. John Cush @RheumNow ( View Tweet )
5 hours 14 minutes ago
The Hidden Cost of Gout
For many people, gout is viewed as an episodic disease: a painful flare, a short course of treatment, and then life returns to normal. However, as rheumatologists, we know that recurrent attacks can lead to joint damage and tophi if left untreated. https://t.co/RWTp5KKkyw
Dr. John Cush @RheumNow ( View Tweet )
19 hours 15 minutes ago
Fibromyalgia: Diagnosis and Management
https://t.co/L9nA1TlJKx https://t.co/G4bkxTsXCt
Dr. John Cush @RheumNow ( View Tweet )
20 hours 45 minutes ago
EUSTAR scleroderma substudy propensity matched pts Rx w/ JAKi (n 38) vs 180 pts ea Rx w/ MMF, MTX, RTX. 1/3 had dcSSc. 23 AEs in 997 Pt-yrs. JAKi outcomes similar to comparators. JAKi Tx D/C in 39%, FVC stable, skin fibrosis improved (mRSS −1.8) & SJC decreased. No new
Dr. John Cush @RheumNow ( View Tweet )
21 hours 9 minutes ago
QD Clinic: Gout, Sepsis… or Both?
Dr. Mrinalini Dey, London, discusses a complex case.
https://t.co/UtncfZgZyL https://t.co/xVTA0LnPpN
Dr. John Cush @RheumNow ( View Tweet )
21 hours 16 minutes ago
The Lancet Rheumatology has a good editorial about the avacopan bad news reports with EMA, FDA and Japan issuing negative opinions that threaten the drugs future. Yet, since approval real world data on avacopan has been favorable w/ less steroid toxicity & most hepatotoxicity https://t.co/k6ebVeWv2K
Dr. John Cush @RheumNow ( View Tweet )
21 hours 57 minutes ago
SGLT2 inhibitors lower serum urate AND reduce gout flares — and may close the mortality gap (CV mortality benefit) and offer renal protection.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/QywxaTSSv6
Dr. John Cush @RheumNow ( View Tweet )
23 hours ago
"Leeuwenhoek (invented the microscope) examined uric acid (C5H4N4O3) crystals from gout patients and found them to resemble needles. He expounded on his observations in an 11 July 1679 letter responding to an earlier query from Mr. Lambert van Velthuysen (1622–1685), a physician, https://t.co/mY2wqYlRda
Dr. John Cush @RheumNow ( View Tweet )
23 hours ago
Primary biliary cholangitis is a chronic cholestatic disease characterized by autoimmune-mediated destruction of bile ducts, leading to fibrosis, cirrhosis, & liver failure. Ursodeoxycholic acid is 1st line Rx. New Rx include elafibranor & seladelpar (activates peroxisome https://t.co/EYcleKlTIB
Dr. John Cush @RheumNow ( View Tweet )
23 hours 52 minutes ago


